Neuropsychological test-based risk prediction of conversion to dementia in amnestic mild cognitive impairment patients: a personal view

IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Precision and Future Medicine Pub Date : 2018-06-29 DOI:10.23838/PFM.2018.00065
Jun Pyo Kim, Hye-ryeon Jang, Hee Jin Kim, D. Na, S. Seo
{"title":"Neuropsychological test-based risk prediction of conversion to dementia in amnestic mild cognitive impairment patients: a personal view","authors":"Jun Pyo Kim, Hye-ryeon Jang, Hee Jin Kim, D. Na, S. Seo","doi":"10.23838/PFM.2018.00065","DOIUrl":null,"url":null,"abstract":"The amnestic form of mild cognitive impairment (aMCI) is understood to be a prodromal state of Alzheimer’s disease dementia. As recent studies and clinical trials have started to focus on the early detection of and intervention for Alzheimer’s disease, aMCI has become an important area of study. Due to the heterogeneous clinical course of aMCI, it is often more challenging for a clinician to predict the prognosis of aMCI patients than of those with Alzheimer’s disease dementia patients. Therefore, the ability to predict the clinical course of an aMCI patient based on the patient’s clinical data is crucial in both clinical and research settings. In the current study, we present our findings on the structural and prognostic differences between aMCI and Alzheimer’s disease dementia according to neuropsychological test results. Additionally, we introduce a neuropsychological test-based risk prediction model of the conversion to dementia.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision and Future Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23838/PFM.2018.00065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

The amnestic form of mild cognitive impairment (aMCI) is understood to be a prodromal state of Alzheimer’s disease dementia. As recent studies and clinical trials have started to focus on the early detection of and intervention for Alzheimer’s disease, aMCI has become an important area of study. Due to the heterogeneous clinical course of aMCI, it is often more challenging for a clinician to predict the prognosis of aMCI patients than of those with Alzheimer’s disease dementia patients. Therefore, the ability to predict the clinical course of an aMCI patient based on the patient’s clinical data is crucial in both clinical and research settings. In the current study, we present our findings on the structural and prognostic differences between aMCI and Alzheimer’s disease dementia according to neuropsychological test results. Additionally, we introduce a neuropsychological test-based risk prediction model of the conversion to dementia.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于神经心理学测试的健忘轻度认知障碍患者转化为痴呆的风险预测:个人观点
轻度认知障碍(aMCI)的遗忘形式被认为是阿尔茨海默病痴呆的前驱状态。随着近年来的研究和临床试验开始关注阿尔茨海默病的早期发现和干预,aMCI已成为一个重要的研究领域。由于aMCI的临床病程具有异质性,临床医生预测aMCI患者的预后往往比预测阿尔茨海默病痴呆患者的预后更具挑战性。因此,根据患者的临床数据预测aMCI患者的临床病程的能力在临床和研究环境中都至关重要。在目前的研究中,我们根据神经心理学测试结果提出了aMCI和阿尔茨海默病痴呆之间的结构和预后差异的研究结果。此外,我们介绍了一种基于神经心理学测试的痴呆症转化风险预测模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Precision and Future Medicine
Precision and Future Medicine MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
15
审稿时长
10 weeks
期刊最新文献
Survival rate and death risk for associated pulmonary arterial hypertension: A retrospective population-based study Understanding hikikomori syndrome in clinical settings: a case series Development of colistin resistance via heteroresistance modeling in Klebsiella pneumoniae: A diagnostic study Paraneoplastic neurological syndrome associated with onconeural autoantibodies: report of two cases Durable response to first-line treatment with AZD3759 (zorifertinib) in a patient with epithelial growth factor receptor mutated non-small cell lung cancer and untreated multiple brain metastasis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1